Bone metastasis of highly differentiated squamous lung cancer belongs to advanced stage lung cancer, and the treatment is mainly systemic treatment, which includes bone-modifying drug therapy, chemotherapy, targeted drug therapy, immunotherapy, radiotherapy and surgery. 1. Bone-modifying drug therapy: common drugs are bisphosphonates and denosumab. Bisphosphonates, such as zoledronic acid, can reduce the pain caused by tumor bone metastasis, and denosumab can inhibit bone resorption and enhance bone density. 2. Chemotherapy: The preferred chemotherapy program is platinum-containing double-drug combination chemotherapy, and the common program is etoposide combined with platinum drugs such as carboplatin or cisplatin. 3. Targeted drug therapy: according to the results of tumor cell gene test, patients can choose appropriate targeted drugs, common drugs such as epidermal growth factor target drugs (gefitinib, ectinib, etc.), vascular endothelial growth factor receptor site target drugs (bevacizumab, etc.). 4. Immunotherapy: common drugs are PD-1 antibodies such as tirilizumab, which provide options for the treatment of patients with advanced lung cancer. 5. Radiation therapy: it is one of the effective treatments for bone metastasis of lung cancer, which can reduce patients’ symptoms and improve their quality of life. External radiation therapy is the first choice of palliative chemotherapy for patients with bone metastases. 6. Surgery: palliative surgery can be performed on bone metastasis for patients with aggravation of bone destruction, continuous aggravation of pain, inability of motor system to recover, and nerve compression. For patients with bone metastasis of squamous lung cancer, they should go to relevant departments of regular hospitals for consultation and treatment to avoid delay.